Short Description

Solid tumor Combo2 [MSI,NRAS,KRAS,BRAF,H RAS] is performed using Sanger Sequencing,Fragment analysis methodology. Sample that have to be given is Tumor tissue+Peripheral blood in Paraffin embedded tissue blocks+ EDTA Vacutainer (2ml) for this test. You can expect results in 10 days

PreTest Information

Solid tumor Combo2 [MSI,NRAS,KRAS,BRAF,H RAS] can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.

Detail Description

Solid Tumor Combo2 [MSI,NRAS,KRAS,BRAF,H RAS] Cost INR:36000 Symptoms Diagnosis

When it comes to diagnosing solid tumors, DNA testing has proven to be an invaluable tool. The Solid Tumor Combo2 panel, which includes MSI, NRAS, KRAS, BRAF, and H RAS genes, is a powerful test that can help identify genetic mutations that may be driving tumor growth. This test is available at DNA Labs India for a cost of INR 36000, making it an affordable option for patients seeking accurate and reliable tumor diagnosis.

Symptoms of Solid Tumors

Solid tumors are masses of abnormal cells that form in various parts of the body. These tumors can be either benign or malignant and can cause a range of symptoms depending on their location and size. Some of the common symptoms of solid tumors include:

• Pain or discomfort in the affected area
• Swelling or lumps
• Changes in bowel or bladder habits
• Unexplained weight loss
• Fatigue or weakness
• Fever or night sweats

If you are experiencing any of these symptoms, it is important to consult with a healthcare provider for further evaluation and testing.

Diagnosing Solid Tumors

Diagnosing solid tumors typically involves a combination of imaging tests, such as CT scans or MRIs, and biopsies, where a small sample of tissue is removed for analysis. DNA testing can also be a valuable tool in the diagnostic process, as it can help identify genetic mutations that may be driving tumor growth. The Solid Tumor Combo2 panel offered at DNA Labs India is a comprehensive test that analyzes five genes commonly associated with solid tumors.

Understanding the Solid Tumor Combo2 Panel

The Solid Tumor Combo2 panel analyzes the following genes:

• MSI (microsatellite instability): This gene is commonly mutated in colorectal, endometrial, and other solid tumors, and can help predict response to certain treatments.
• NRAS: Mutations in this gene are commonly found in melanoma, colorectal, and lung cancers, and can help guide treatment decisions.
• KRAS: Mutations in this gene are commonly found in pancreatic, colorectal, and lung cancers, and can help guide treatment decisions.
• BRAF: Mutations in this gene are commonly found in melanoma, thyroid, and colorectal cancers, and can help guide treatment decisions.
• H RAS: Mutations in this gene are commonly found in bladder, kidney, and thyroid cancers, and can help guide treatment decisions.

By analyzing these genes, the Solid Tumor Combo2 panel can provide valuable information about the genetic makeup of a tumor, helping healthcare providers make more informed treatment decisions.

The Cost of the Solid Tumor Combo2 Panel

The Solid Tumor Combo2 panel is available at DNA Labs India for a cost of INR 36000. This cost includes the analysis of all five genes and a detailed report outlining the results. While this cost may seem high, it is important to remember that accurate diagnosis is a critical component of effective cancer treatment. By identifying the specific genetic mutations driving a tumor, healthcare providers can tailor treatment plans to the unique needs of each patient, potentially improving outcomes and reducing the need for more invasive interventions.

Conclusion

The Solid Tumor Combo2 panel is a powerful tool for diagnosing solid tumors and identifying genetic mutations that may be driving tumor growth. This test, available at DNA Labs India for a cost of INR 36000, is an affordable option for patients seeking accurate and reliable tumor diagnosis. If you are experiencing symptoms of a solid tumor, it is important to consult with a healthcare provider for further evaluation and testing.